Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study
Objective. To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment. Methods. This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases. Infan...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2017/5078565 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850161451972427776 |
|---|---|
| author | Qinrui Hu Yujing Bai Xiaoli Chen Lvzhen Huang Yi Chen Xiaoxin Li |
| author_facet | Qinrui Hu Yujing Bai Xiaoli Chen Lvzhen Huang Yi Chen Xiaoxin Li |
| author_sort | Qinrui Hu |
| collection | DOAJ |
| description | Objective. To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment. Methods. This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases. Infants who developed Zone II Stage 3 ROP with plus disease and underwent initial intravitreal injection of ranibizumab (IVR) were recruited. Patients were divided into 2 groups based on the outcome after initial ranibizumab treatment: recurrence of ROP or favorable outcome. Data was collected and analyzed by SPSS 16.0. Results. Forty-two patients were included, and 80 eyes with Zone II Stage 3+ were subjected to IVR treatment. Eleven of 42 patients (26.2%, 18 eyes) had a recurrence of ROP after the initial treatment. On univariate analysis, preretinal hemorrhage before treatment was significantly different between the two groups (P=0.000). Multivariate analysis found that preretinal hemorrhage before treatment was the only factor associated with the recurrence of ROP in our study (P=0.004). Conclusions. The recurrence rate of ROP in Zone II Stage 3+ after initial ranibizumab treatment was notable and preretinal hemorrhage before treatment was associated with the recurrence of ROP in our study. |
| format | Article |
| id | doaj-art-ff6e0369fc8341c1bb906f4e02bacd88 |
| institution | OA Journals |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-ff6e0369fc8341c1bb906f4e02bacd882025-08-20T02:22:50ZengWileyJournal of Ophthalmology2090-004X2090-00582017-01-01201710.1155/2017/50785655078565Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective StudyQinrui Hu0Yujing Bai1Xiaoli Chen2Lvzhen Huang3Yi Chen4Xiaoxin Li5Department of Ophthalmology, Peking University People’s Hospital, Beijing Key Laboratory for the Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing, ChinaDepartment of Ophthalmology, Peking University People’s Hospital, Beijing Key Laboratory for the Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing, ChinaDepartment of Ophthalmology, Peking University People’s Hospital, Beijing Key Laboratory for the Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing, ChinaDepartment of Ophthalmology, Peking University People’s Hospital, Beijing Key Laboratory for the Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing, ChinaDepartment of Ophthalmology, China-Japan Friendship Hospital, Beijing, ChinaDepartment of Ophthalmology, Peking University People’s Hospital, Beijing Key Laboratory for the Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing, ChinaObjective. To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment. Methods. This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases. Infants who developed Zone II Stage 3 ROP with plus disease and underwent initial intravitreal injection of ranibizumab (IVR) were recruited. Patients were divided into 2 groups based on the outcome after initial ranibizumab treatment: recurrence of ROP or favorable outcome. Data was collected and analyzed by SPSS 16.0. Results. Forty-two patients were included, and 80 eyes with Zone II Stage 3+ were subjected to IVR treatment. Eleven of 42 patients (26.2%, 18 eyes) had a recurrence of ROP after the initial treatment. On univariate analysis, preretinal hemorrhage before treatment was significantly different between the two groups (P=0.000). Multivariate analysis found that preretinal hemorrhage before treatment was the only factor associated with the recurrence of ROP in our study (P=0.004). Conclusions. The recurrence rate of ROP in Zone II Stage 3+ after initial ranibizumab treatment was notable and preretinal hemorrhage before treatment was associated with the recurrence of ROP in our study.http://dx.doi.org/10.1155/2017/5078565 |
| spellingShingle | Qinrui Hu Yujing Bai Xiaoli Chen Lvzhen Huang Yi Chen Xiaoxin Li Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study Journal of Ophthalmology |
| title | Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study |
| title_full | Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study |
| title_fullStr | Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study |
| title_full_unstemmed | Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study |
| title_short | Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study |
| title_sort | recurrence of retinopathy of prematurity in zone ii stage 3 after ranibizumab treatment a retrospective study |
| url | http://dx.doi.org/10.1155/2017/5078565 |
| work_keys_str_mv | AT qinruihu recurrenceofretinopathyofprematurityinzoneiistage3afterranibizumabtreatmentaretrospectivestudy AT yujingbai recurrenceofretinopathyofprematurityinzoneiistage3afterranibizumabtreatmentaretrospectivestudy AT xiaolichen recurrenceofretinopathyofprematurityinzoneiistage3afterranibizumabtreatmentaretrospectivestudy AT lvzhenhuang recurrenceofretinopathyofprematurityinzoneiistage3afterranibizumabtreatmentaretrospectivestudy AT yichen recurrenceofretinopathyofprematurityinzoneiistage3afterranibizumabtreatmentaretrospectivestudy AT xiaoxinli recurrenceofretinopathyofprematurityinzoneiistage3afterranibizumabtreatmentaretrospectivestudy |